

Amendments to the Claims


This claim set replaces all previous claims in this application.

1. (Currently amended) A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and:

(a) an inhibitor of the RSV fusion protein; and

(b) a benzodiazepine derivative capable of inhibiting RSV replication

wherein component (a) is a compound of formula (I), or a pharmaceutically acceptable salt thereof,



wherein:

X is a direct link or C₁₋₆ alkyl; said C₁₋₆ alkyl being optionally substituted with halogen, oxo, cyano, OCOR₄ or S(O)_n-C₁₋₆ alkyl;

Y is R₄, NR₄R₅, NCOR₄, =N-OR₄, -CONHR₄, COOR₄, -OR₄, aryl, heteroaryl, cyclyl or heterocyclyl, where R₄ and R₅ are H or C₁₋₆ alkyl;

Z is CR₆R', where R₆ is H, or straight, branched or cyclic C₁₋₆ alkyl and R' is straight, branched or cyclic C₁₋₆ alkyl;

n is 1-2;

R₁ is H, CONR₄R₅, CO₂R₄ or C₁₋₆ alkyl, said C₁₋₆ alkyl can be optionally substituted with OR₄ or NR₈R₉;


R₈ and R₉ are each independently H, C₁₋₆ alkyl, SO₂R₅, CO₂R₄ or COR₄;

R₂ is selected from the group consisting of H, NH₂, CONR₆R', heteroaryl, C₂₋₆ alkenyl, CO₂R₄, N=CPh₂, C(=NH)NH₂ and C₁₋₆ alkyl; said alkyl optionally substituted with a member selected from the group consisting of halogen, CN, NR₁₀R₁₁, OSO₂R₄ and OR₄;

R₁₀ and R₁₁ are each independently selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, CO₂R₄, COR₄ and SO₂R₄;

R₃ is selected from the group consisting of (1) CO₂R₉; (2) C₁₋₆ alkyl optionally substituted with CN, OR₄ or NR₆R'; (3) H; and (4) C₂₋₆ alkenyl substituted with CN;


Q is a member selected from the group consisting of



A is C or N, optionally substituted with H, halogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, cyano-C₁₋₆ alkyl, CO₂R₄, aryl, benzoaminocarbonyl, hydroxybenzyl, SO₂NR₄R₅ or C₃₋₆ cycloalkyl. Where A is carbon, it may also be optionally substituted by O or S via a double bond;

B is C or N; where B is C it may be optionally substituted by H, C₁₋₆ alkyl, NO₂, CN, halogen, COR₄, COOR₄, CONHR₄C(=NH)NH₂ or C(=N0H)NH₂.

2. (Previously presented) A composition according to claim 1, wherein component (b) is a compound of formula (V), or a pharmaceutically acceptable salt thereof,



wherein:

R¹ represents C₁₋₆ alkyl, aryl or heteroaryl;

R² represents hydrogen or C₁₋₆ alkyl;

each R³ is the same or different and represents halogen, hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, amino, mono(C₁₋₆ alkyl)amino, di(C₁₋₆ alkyl)amino, nitro, cyano, -CO₂R', -CONR'R'', -NH-CO-R', -S(O)R', -S(O)₂R', -NH-S(O)₂R', -S(O)NR'R'' or -S(O)₂NR'R'', wherein each R' and R'' is the same or different and represents hydrogen or C₁₋₆ alkyl;

n is from 0 to 3;

R⁴ represents hydrogen or C₁₋₆ alkyl;

R⁵ represents C₁₋₆ alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)-, heterocyclyl-(C₁₋₆ alkyl)-, aryl-(C₁₋₆

hydroxyalkyl)-, heteroaryl-(C₁₋₆ hydroxyalkyl)-, carbocyclyl-(C₁₋₆ hydroxyalkyl)-, heterocyclyl-(C₁₋₆ hydroxyalkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or -XR⁶;

X represents -CO-, -S(O)- or -S(O)₂-; and

R⁶ represents C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)-, heterocyclyl-(C₁₋₆ alkyl)-, aryl-(C₁₋₆ alkyl)-O-, heteroaryl-(C₁₋₆ alkyl)-O-, carbocyclyl-(C₁₋₆ alkyl)-O-, heterocyclyl-(C₁₋₆ alkyl)-O- or -NR'R'' wherein each R' and R'' is the same or different and represents hydrogen, C₁₋₆ alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)- or heterocyclyl-(C₁₋₆ alkyl)-.

3. (Original) A composition according to claim 2 wherein:

each R³ is the same or different and represents halogen, hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, amino, mono(C₁₋₆ alkyl)amino, di(C₁₋₆ alkyl)amino, nitro, cyano, -CO₂R', -CONR'R'', -NH-CO-R', -S(O)R', -S(O)₂R', -NH-S(O)₂R' or -S(O)NR'R'', wherein each R' and R'' is the same or different and represents hydrogen or C₁₋₆ alkyl ;

R represents C₁₋₆ alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)-, heterocyclyl-(C₁₋₆ alkyl)- or -XR⁶;

X represents -CO-, -S(O)- or -S(O)₂-; and

R⁶ represents C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)-, heterocyclyl-(C₁₋₆ alkyl)- or -NR'R'' wherein each R' and R'' is the same or different and represents hydrogen, C₁₋₆ alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C₁₋₆ alkyl)- or heteroaryl-(C₁₋₆ alkyl)-.

4. (Previously presented) A composition according to claim 2, wherein R¹ is C₁₋₂ alkyl or aryl.

5. (Previously presented) A composition according to claim 2 wherein R² is hydrogen.

6. (Previously presented) A composition according to claim 2 wherein R^3 is halogen, hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, amino, mono(C_{1-4} alkyl)amino or di(C_{1-4} alkyl)amino.
7. (Original) A composition according to claim 6, wherein R^3 is fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl, C_{1-2} haloalkoxy, amino, mono(C_{1-2} alkyl)amino or di (C_{1-2} alkyl)amino.
8. (Previously presented) A composition according to claim 2 wherein R^4 is hydrogen or C_{1-2} alkyl.
9. (Previously presented) A composition according to claim 2 wherein R^5 is C_{1-6} alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl- $(C_{1-4}$ alkyl)-, heteroaryl- $(C_{1-4}$ alkyl)-, carbocyclyl- $(C_{1-4}$ alkyl)-, heterocyclyl- C_{1-4} alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or - XR^6 .
10. (Original) A composition according to claim 9, wherein R^5 is C_{1-4} alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, phenyl- $(C_{1-2}$ alkyl)-, heteroaryl- $(C_{1-2}$ alkyl)-, phenyl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or - XR^6 .
11. (Original) A composition according to claim 10, wherein R^5 is C_{1-4} alkyl, phenyl, thienyl, furanyl, isoxazolyl, pyridyl, cyclopentyl, cyclohexyl, benzothienyl, dihydrobenzofuranyl, phenyl- CH_2 -, furanyl- CH_2 -, phenyl-C(O)-C(O)-, thienyl-C(O)-C(O)- or - XR^6 .
12. (Previously presented) A composition according to claim 2 wherein, X is -CO- or -S(O)₂-.
13. (Previously presented) A composition according to claim 2 wherein, when R^6 is a group NR'R'' wherein each R' and R'' is the same or different and represents hydrogen, C_{1-4} alkyl, aryl, carbocyclyl, heterocyclyl, aryl- $(C_{1-4}$ alkyl)- or heteroaryl- $(C_{1-4}$ alkyl)-.

14. (Original) A composition according to claim 13, wherein when R^6 is a group $-NR'R''$ each R' and R'' is the same or different and represents hydrogen, C_{1-4} alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl- CH_2 -.


15. (Original) A composition according to claim 14, wherein when R^6 is a group $-NR'R''$ and one of R' and R'' is hydrogen.

16. (Previously presented) A composition according to claim 2 wherein R^6 is C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl- $(C_{1-4}$ alkyl)-, heteroaryl- $(C_{1-4}$ alkyl)-, carbocyclyl- $(C_{1-4}$ alkyl)-, heterocyclyl- $(C_{1-4}$ alkyl)-, aryl- $(C_{1-4}$ hydroxyalkyl)-, heteroaryl- $(C_{1-4}$ hydroxyalkyl)-, carbocyclyl- $(C_{1-4}$ hydroxyalkyl)-, heterocyclyl- $(C_{1-4}$ hydroxyalkyl)-, aryl- $(C_{1-4}$ alkyl)-O-, heteroaryl- $(C_{1-4}$ alkyl)-O-, carbocyclyl- $(C_{1-4}$ alkyl)-O-, heterocyclyl- $(C_{1-4}$ alkyl)-O- or $-NR'R''$.

17. (Original) A composition according to claim 16, wherein R^6 is C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, phenyl- $(C_{1-2}$ alkyl)-, phenyl- $(C_{1-2}$ alkyl)-O-, heteroaryl- $(C_{1-2}$ alkyl)-, phenyl- $(C_{1-2}$ hydroxyalkyl)-, heteroaryl- $(C_{1-2}$ hydroxyalkyl)- or $-NR'R''$.

18. (Original) A composition according to claim 17, wherein R^6 is C_{1-4} alkyl, C_{1-4} alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl- $(C_{1-2}$ alkyl)-, phenyl- $CH_2-CH(OH)-$, phenyl- $CH(OH)-CH_2-$, phenyl- $(C_{1-2}$ alkyl)-O-, 1H-benzo[d]imidazol-2(3H)-onyl or $-NR'R''$.

19. (Previously presented) A composition according to claim 2 wherein the benzodiazepine derivative of formula (V) is a benzodiazepine derivative of formula



wherein:

R^1 is phenyl or methyl;

R^3 is methyl or chlorine;

n is 0 or 1;

R^4 is hydrogen or methyl;

R^5 is phenyl-CH₂-, furanyl-CH₂-, thienyl-C(O)-C(O)- or -XR⁶;

X is -CO- or -S(O)₂-; and

R^6 is C₁₋₄ alkyl, C₁₋₄ alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(C₁₋₂ alkyl)-, phenyl-CH₂-CH(OH)-phenyl-CH(OH)-CH₂-, phenyl-(C₁₋₂ alkyl)-O-, 1H-benzo[d]imidazol-2(3H)-onyl or -NR'R'' wherein each R' and R'' is the same or different and represents hydrogen, C₁₋₄ alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH₂)-, the phenyl moiety in the group R^1 being unsubstituted or substituted by a single fluorine, chlorine, C₁₋₂ alkyl, C₁₋₂ alkoxy, C₁₋₂ alkylthio, C₁₋₂ haloalkyl or C₁₋₂ haloalkoxy substituent;

the aryl moieties in the groups R^5 and R^6 being unsubstituted or substituted by 1, 2 or 3 substituents selected from fluorine, chlorine, bromine, iodine, C₁₋₄ alkyl, C₂₋₄ acyl, hydroxy, C₁₋₄ alkoxy, C₁₋₄ alkylthio, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, amino, mono(C₁₋₄ alkyl)amino, di(C₁₋₄ alkyl)amino, nitro, -CO₂R', -S(O)₂R' and -S(O)₂NH₂, wherein R' represents C₁₋₂ alkyl;

the heteroaryl moieties in the groups R^5 and R^6 being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C₁₋₂ alkyl, C₁₋₂ haloalkyl and di(C₁₋₂ alkyl)amino; and

the heterocyclyl and carbocyclyl moieties in the R^6 group being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl and nitro.

20. (Original) A composition according to claim 1, wherein the benzodiazepine derivative of formula (V) is:

Cyclohexanecarboxylic acid 2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

3-Methoxy N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

4-Methoxy N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
2-Methoxy N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-trifluoromethyl-
benzamide;
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
Thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-
yl)-3-amide;
Furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-
amide;
Piperidine-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-
yl)-amide;
Morpholine-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3 -
yl)-amide;
4-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
3-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
4-Methyl-piperazine-1-carboxylic acid-(2-oxo-5-phenyl-2,3-dihydro-1H-
benzo[e][1,4]diazepin-3-yl)-amide;
3,4-Dichloro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-trifluoromethyl-
benzamide;
4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
2-Methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
2-Chloro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
2-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-
benzamide;
(S)-2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-
benzamide
Benzo[b]thiophene-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1 H-benzo[e]
[1,4]diazepin-3-yl)-amide;

2,3-Dihydro-benzofuran-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

Isoxazole-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;

Benzo[b]thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

Thiophen-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-isonicotinamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-nicotinamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-methanesulfonamide;

Propane-1-sulfonic acid-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;

Butane-1-sulfonic acid-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

2-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzenesulfonamide;

3-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzenesulfonamide;

4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzenesulfonamide;

2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzenesulfonamide;

3-(2-Nitro-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;

3-(3-Nitro-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;

3-(4-Nitro-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;

3-(2-Methoxy-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;

3-(3-Methoxy-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;

5-Phenyl-3-(2-trifluoromethyl-benzylamino)-1,3-dihydro-benzo[e][1,4]diazepin-2-one;

5-Phenyl-3-(3-trifluoromethyl-benzylamino)-1,3-dihydro-benzo[e][1,4]diazepin-2-one;

5-Phenyl-3-(4-trifluoromethyl-benzylamino)-1,3-dihydro-benzo[e][1,4]diazepin-2-one;

3-[(Furan-2-ylmethyl)-amino]-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide;
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-isobutyramide;
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-methanesulfonamide;
Furan-2-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
Thiophene-2-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
Cyclohexanecarboxylic acid (7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-methoxybenzamide;
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-methoxybenzamide;
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-nitrobenzamide;
2-(2-Methoxy-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide;
2-(3-Methoxy-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide;
2-(4-Methoxy-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide;
2-(4-Nitro-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide;
2-(3-Nitro-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide;
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(2-trifluoromethylphenyl)-acetamide;
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(3-trifluoromethylphenyl)-acetamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(4-trifluoromethyl-phenyl)-acetamide;

1-(2-Methoxy-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-urea;

1-(2-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(2-Chloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(4-Chloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-p-tolyl-urea;

1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(4-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-urea;

(S)-1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-urea;

4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-benzamide;

6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-trifluoromethyl-benzamide;

2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)-2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

1H-Indole-7-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;

(S)-1H-Indole-7-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

3-Methoxy-naphthalene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-3-Methoxy-naphthalene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

N-[7-Chloro-5-(2-fluoro-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepine-3-yl]-4-methoxy-benzamide;

1-(2-Fluoro-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(4-Methoxy-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-urea;

1-(3-Methyl-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-trifluoromethyl-phenyl)-urea;

4-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

4-Methoxy-3-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide;

3-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

5-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide;

5-Fluoro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

5-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

3-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

3-(2-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide;

3-(3-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide;

3-(4-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide;

N-[5-(3-Chloro-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-methoxybenzamide;

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-methoxybenzamide;

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-nitrobenzamide;

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-nitrobenzamide;

4-Methoxy-N-[2-oxo-5-(4-trifluoromethyl-phenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-benzamide;

2-Methoxy-N-[2-oxo-5-(3-trifluoromethyl-phenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-benzamide;

4-Methoxy-N-[2-oxo-5-(3-trifluoromethyl-phenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-benzamide;

2-Ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

2,4-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

2-Bromo-5-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

2-Methoxy-N-[5-(3-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-benzamide

N-[5-(3-Methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-nitro-benzamide;

2-Methoxy-N-(8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

2-Chloro-4-methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

2-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid benzyl ester;

1-(3,5-Dimethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-trifluoromethoxy-phenyl)-urea;

1-(4-Bromo-2-trifluoromethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(4-Bromo-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(2,3-Dichloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(2,6-Dimethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(2-Chloro-6-methyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(4-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(2-Methylsulfonyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(2,6-Dichloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-urea;

5-tert-Butyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

2,5-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

1 -(2,6-Difluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-urea;

1-(3-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(3-Methoxy-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-urea;

1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(3-trifluoromethyl-phenyl)-urea;

1-(3-Chloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

2-Methoxy-4-methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

4-Methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)terephthalamic acid methyl ester;

2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

2,6-Difluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-propoxy-benzamide;

2-Iodo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

3-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-terephthalamic acid methyl ester;

4-Amino-5-chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-m-tolyl-urea;

2-Methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-5-sulfamoyl-benzamide;

2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenyl-propionamide

3-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenyl-propionamide;

3-(2-Fluoro-phenyl)-1-methyl-1-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

2-Methoxy-N-methyl-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

1-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-Cycloheptyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-Ethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

4,5-Dimethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide;

Piperidine-1-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide;

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-isobutyramide;

Furan-2-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

Thiophene-2-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

Cyclohexanecarboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

Piperidine-1-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]isonicotinamide;

5-Methyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

Pyrazine-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

N-[5-(3-Methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-isobutyramide;

Thiophene-2-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

Cyclohexanecarboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

Piperidine-1-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

Piperidine-4-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

Cyclohexanecarboxylic acid (8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

Thiophene-2-carboxylic acid (8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-thiophene-2-yl-urea;

1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-thiophene-3-yl-urea;

Pyridine-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

1H-Pyrazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

6-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

2-Ethoxy-naphthalene-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

9-Oxo-9H-fluorene-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

2-Oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid tert-butyl ester;

(S)-4,5-Dibromo-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-Benzofuran-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid methyl ester;

(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid ethyl ester;

(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid isobutyl ester; and

2-Oxo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-thiophene-2-yl-acetamide.


21. (Previously presented) A composition according to claim 2, wherein the benzodiazepine derivative of formula (V) is 1-(2-fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea, 2-methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide or 4-methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide.

22. (Original) A composition according to claim 21, wherein the benzodiazepine derivative of formula (V) is 1-(2-fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea.

23. (Cancelled)


24. (Currently amended) A composition according to claim 1 ~~claim 23~~, wherein at least two of R₁, R₂ and R₃ are hydrogen, and the other is hydrogen or -C(NH)-NH₂ and/or either -X-Y is

H, or X is a C₁-C₆ alkylene group which is unsubstituted or substituted by a hydroxy group and Y is H, OH, CN, -NR'R'', -COR', -SO₂R' or phenyl, wherein R' and R'' are the same or different and represent a C₁-C₄ alkyl group and/or Z is -CH₂- and/or Q is a moiety



wherein B is -CH- or -N-, A₁ is -C(O)- or -NH- and A₂ is -CH₂-, -CHR'- or -NR''-, wherein R' is a halogen atom and R'' represents a hydrogen atom or a C₁₋₄ alkyl, C₂₋₄ alkenyl, C₃₋₆ cycloalkyl, -SO₂-(C₁₋₆ alkyl), -SO₂-N(C₁₋₆ alkyl)₂ or -(CO-NH)_a-(C₁₋₄ alkyl)-phenyl group, wherein a is 0 or 1, which group is unsubstituted or is substituted with a hydroxy or cyano substituent.

25. (Withdrawn) A composition according to claim 1, wherein component (a) is a compound of the formula (II), or a pharmaceutically acceptable salt thereof



wherein:

- L₁ is -CH₂- or -CHR₂-CO-
- each X is the same or different and is CH or N;
- each R₁ is the same or different and is C₁₋₆ alkyl, halogen, hydroxy, phenyl or (CH₂)_m=NH₂;
- n is 1 or 2;
- R₂ is C₁₋₆ alkoxy or C₁₋₆ alkoxy-phenyl;
- R₃ is C₁₋₆ alkyl;
- L₂ is -CH₂- or -NH-;
- Y is C₁₋₆ alkyl or C₁₋₆ alkenyl;

Z is H, N(R₄)₂-, -C(=O)-R₅, -C(=CH₂)-R₅, -CH(OH)-R₅, -CH(CH₃)-R₅, -CH(OCH₃)-R₅; each R₄ is the same or different and is H, C1-6 alkyl.

R₅ is C₁₋₆alkyl-carbonyl, amino, hydroxyl, aryl, heteroaryl, carbocyclyl, heterocyclyl; and m = 1-6

26. (Previously presented) A composition according to claim 1, wherein component (a) is:

1-Cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-imidazo[4, 5-c]pyridin-2-one

{2-[2-(1,2-Dihydro-benzotriazol-1-ylmethyl)-benzoimidazol-1-yl]]ethyl}-diethyl-amine

{2-[2-(3-Iodo-2,3-dihydro-indazol-1-ylmethyl)-benzimidazol-1-yl]-ethyl}-dimethyl-amine

1-Isopropenyl-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-(4-Hydroxy-benzyl)-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-Isopropenyl-3-[1-(3-oxo-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-Ethyl-3-[1-(2-hydroxy-2-phenyl-ethyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-Ethyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

7-[2-(3-Isopropenyl-2-oxo-2,3-dihydrobenzoimidazol-1-ylmethyl)-benzoimidazol-1-yl]-heptanenitril

5-{3-[1-(3-Methanesulfonyl-propyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-yl}-pentanenitrile

3-[1-(3-Methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-carboxylic acid benzylamide

1-Methanesulfonyl-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

3-[1-(3-Methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-sulfonic acid dimethylamide

1-Isopropenyl-3-(1-propyl-1H-benzoimidazol-2-ylmethyl)-1,3-dihydro-imidazo[4,5-c]pyridine-2-one

Bis(5-amidino-2-benzimidazolyl)-methane

2-{2-[1-[1-(2-Amino-ethyl)-piperidin-4-ylamino]-4-methyl-benzoimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol

or a pharmaceutically acceptable salt thereof.

27. (Previously presented) A composition according to claim 1, wherein component (a) is 1-cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-imidazo[4,5-c]pyridin-2-one, {2-[2-(1,2-dihydro-benzotriazol-1-ylmethyl)-benzoimidazol-1-yl]] ethyl}-diethyl-amine, {2-[2-(3-iodo-2,3-dihydro-indazol-1-ylmethyl)-benzimidazol-1-yl]-ethyl}-dimethyl-amine or a pharmaceutically acceptable salt thereof.

28. (Previously presented) A composition according to claim 1, wherein component (a) is 1-cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-imidazo[4,5-c]pyridin-2-one or 1-Isopropenyl-3-(1-propyl-1H-benzoimidazol-2-ylmethyl)-1,3-dihydro-imidazo[4,5-c]pyridine-2-one or a pharmaceutically acceptable salt thereof.

29. (Previously presented) A composition according to claim 1, wherein component (a) is present in an amount of from 0.025 wt% to 10 wt%.

30. (Previously presented) A composition according to claim 1, wherein component (b) is present in an amount of 0.025 wt% to 10 wt%.

31. (Previously presented) A composition according to claim 1, for use in the treatment of the human or animal body.

32. (Previously presented) The use of:

(a) an RSV fusion protein inhibitor as defined in claim 1; and

(b) a benzodiazepine derivative defined in claim 1, in the manufacture of a medicament for use in treating or preventing an RSV infection.

33. (Previously presented) The use according to claim 32, wherein component (a) is present in an amount of from 0.025 wt% to 10 wt% and component (b) is present in an amount of 0.025 wt% to 10 wt%.

34. (Previously presented) A product comprising:

(a) an RSV fusion protein inhibitor as defined in claim 1; and

(b) a benzodiazepine derivative as defined claim 1;

for separate, simultaneous or sequential use in the treatment of the human or animal body.

35. (Currently amended) A product according to claim 34 for separate, simultaneous or sequential use in treating ~~or preventing~~ an RSV infection.

36. (Previously presented) A method of treating or preventing an RSV infection in a patient, which method comprises the administration to said patient of:

(a) an RSV fusion protein inhibitor as defined in claim 1; and

(b) a benzodiazepine derivative as defined in claim 1.

37. (Previously presented) The use of an RSV fusion protein inhibitor as defined in claim 1, in the manufacture of a medicament for use in treating or preventing an RSV infection, by co-administration with a benzodiazepine derivative as defined in claim 1.

38. (Previously presented) The use of a benzodiazepine derivative as defined in claim 1, in the manufacture of a medicament for use in treating or preventing an RSV infection, by co-administration with an RSV fusion protein inhibitor as defined in claim 1.